Who is sponsoring NCT04291105?

NCT04291105 is sponsored by Vyriad, Inc..

What condition does NCT04291105 study?

NCT04291105 studies Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer.

What drugs are being tested in NCT04291105?

Interventions: VV1, Cemiplimab.

What is the status of NCT04291105?

NCT04291105 is currently RECRUITING.

Last reviewed 2025-03-25 · How we verify

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors

NCT04291105 Phase 2 RECRUITING

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.

Details

Lead sponsor	Vyriad, Inc.
Phase	Phase 2
Status	RECRUITING
Enrolment	87
Start date	2020-04-24
Completion	2025-12

Conditions

Melanoma
Head and Neck Squamous Cell Carcinoma
Colo-rectal Cancer

Interventions

VV1
Cemiplimab

Primary outcomes

Objective response rate (ORR) per imaging assessment — within 24 months
Percentage of participants with objective response is assessed every six weeks from Cycle 1 Day 1 through disease progression, by investigator review based on RECIST version 1.1

Countries

United States, Brazil